ArticleStem cell reviews and reports2026
2-Methoxyestradiol Suppresses Stemness and Epithelial-Mesenchymal Transition in Drug-Resistant Esophageal Squamous Cell Carcinoma by Targeting the Snail Signaling Pathway in Cancer Stem Cells.
Article in Stem cell reviews and reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Cancer stem cells (CSCs) and epithelial-mesenchymal transition (EMT) are critical contributors to tumor drug resistance, which represents a major obstacle to successful cancer therapy. 2-Methoxyestradiol (2ME2) is an endogenous metabolite of 17β-estradiol, and accumulating evidence has demonstrated that 2ME2 suppresses stemness and EMT in multiple cancer types. However, whether 2ME2 overcomes drug resistance remains unclear. In this study, 2ME2 was found to inhibit cell viability and increases susceptibility to paclitaxel in drug-resistant esophageal cancer cells. Besides, 2ME2 suppress CSC-like traits and cell migration. Mechanically, 2ME2 inhibited the activation of the TGFβ1/Smad signaling pathway, reduced Snail protein levels by promoting its degradation in paclitaxel-resistant esophageal squamous cell carcinoma cells. Importantly, Snail is at least partially involved in the inhibitory effect of 2ME2 on cell migration in drug-resistant cancer cells. Collectively, our results reveal that 2ME2 effectively attenuates CSC stemness and inhibits EMT to overcome paclitaxel resistance in esophageal cancer. Accordingly, further development of more potent 2ME2 analogs and optimized delivery systems in future preclinical studies is warranted, which may provide therapy strategy for resistant ESCC treatment.Clinical Trial Registration: Not applicable.
Indexed as
Identifiers
42319594What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.